Dupixent clears PhIII trial in new disease as blockbuster looks to expand past Regeneron-Sanofi split
Sanofi and Regeneron may be splitting up, but their billion-dollar baby, Dupixent, keeps on growing.
Already grossing over $2 billion last year based on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
